THE FEMALE HEALTH 

    COMPANY  REPORTS:   

                                                                 

South Africa Expands Female Condom Program

  Order signifies importance of female-controlled methods

 to prevent HIV and other STDs

 

CHICAGO, Mar. 27, 2001– The Female Health Company (OTC BB: FHCO.OB) today announced that it received an order from the National Department of Health of South Africa for 1.4 million Female Condoms.

Because it has the largest number of people living with HIV/AIDS in the world – 4.7 million people, or one in every nine South Africans – South Africa has initiated aggressive prevention programs, including one of the largest and longest-running Female Condom programs.  South Africa first ordered 95,000 Female Condoms in 1996 to test the trial use and acceptability of the product in several provinces.  Since then, South Africa has ordered more than 5 million Female Condoms, including the current order.

            “South Africa continues to be at the forefront of strategically integrating the Female Condom program into HIV/AIDS prevention strategies,” said Mary Ann Leeper, PhD, president of Female Health Company.  “We are delighted to continue our collaboration with the national health department and the Reproductive Health Research Unit to further education about prevention and the Female Condom as a method to help reduce the risk of HIV infection.

“The most recent HIV statistics released last week in South Africa highlight the disturbing trend that women in their early 20s have the highest infection rate,” added Leeper.  “It is precisely this audience that needs access to information, negotiating skills and the Female Condom”.

Based on initial findings from early acceptability research, each of the country’s nine provinces selected two to four demonstration sites for Female Condom distribution.  Extensive training, monitoring and research of the initial pilot programs helped identify attributes for successful introduction, which the Department of Health is using to expand distribution programs.

Among the conclusions during the most recent phase of the introduction are that a substantial number of women have continued using the Female Condom, the Female Condom is sufficiently acceptable to men and women, the Female Condom is a protection complement to the male condom and the Female Condom empowers women to protect themselves.

“The Female Condom is suitable for all women because . . . [it gives] you control.  You are the one who has to insert it, so if anyone does not want to use it, then they can leave,” said one of the participants

“We must increase the number of protected sex acts to reduce the rate of HIV infection in South Africa,” said Professor Helen Rees, executive director of the Reproductive Health Research Unit that oversees the Female Condom strategy for the South African Department of Health.  “We can do this only by ensuring access to effective, affordable and acceptable methods of protection, such as the Female Condom.  Increasingly, individuals and communities are asking for the Female Condom, and we are committed to providing this option for South Africans.”

“The process of moving from pilot program to large-scale, sustainable national program in South Africa is consistent with experiences elsewhere,” said Leeper.  “Almost all of our partners in the United States and internationally have followed this pattern of growth, and are maintaining and often increasing their orders.

“Zimbabwe and South Africa are both examples of countries that have successfully implemented an overall program that incorporates the Female Condom,” added Leeper.  “In Zimbabwe, both the social marketing program run by Population Services International and the public sector program re-ordered in the past month.  Additionally, a recent study of the Zimbabwe social marketing program found that the Female Condom is providing new and additional protection from HIV and other sexually transmitted infections (STIs).”  The study stated, “The Female Condom thus provides a new method of barrier protection previously not achieved.”

UNAIDS supported studies show that when the Female Condom is available as an option, there is a significant reduction in the incidence of sexually transmitted disease (STD) compared to when only the male condom is available.  Additional research, recently published, highlights that incorporating the Female Condom into prevention programs can be cost saving as it reduces the number of unprotected sexual acts, the incidence of STDs, and the costs related to treatment and care.

The Female Condom is the only product controlled by women that helps to prevent STDs, including HIV/AIDS and unintended pregnancy.  The Female Condom is made of polyurethane, which is strong and unlikely to rip or tear during use and unlikely to cause allergic reactions.  It is manufactured in a state of the art facility in London, England.

 The Female Health Company, based in Chicago, owns certain worldwide rights to The Female Condom including patents that have been issued in the United States, United Kingdom, Japan France, Italy, Germany, The People’s Republic of China, Canada, New Zealand, South Korea and Australia. The Female Condom is the only available product controlled by a woman that protects against sexually transmitted diseases including HIV/AIDS, and unintended pregnancy.

 

“Safe Harbor” Statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company’s current plans and strategies, and reflect the Company’s current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of governmental regulations, both in the United States and abroad; the effects of competitive products and pricing pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company’s press releases, shareholder communication and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company’s operations may vary from those currently anticipated.

For more information, dial toll-free via fax 1-800-PRO-INFO, and enter company code “FHCO.”  Also, visit the company’s web site, www.femalehealth.com. 

###

     

For more information about the Female Health Company, dial toll-free via fax,
1-800-PRO-INFO and enter company code “FHCO.”  Also, visit the Company’s Web site at www.femalehealth.com.

 

Investor Contact                        Product Contact                             Media Contact

William R. Gargiulo, Jr.            Mary Ann Leeper, Ph.D.                    Brad Wilks

231.526.1244                              312.280.1119 x223                        312.397.6036